SCHEMBL11943541

SCHEMBL11943541

CCOCCCNc1c(N2CCNCC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 3/20 0.42
ALDH1A1 P00352 3/20 0.41
DCTPP1 Q9H773 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
BRD9 Q9H8M2 1/20 0.39
TSHR P16473 1/20 0.38
GUSB P08236 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13304479 0.89 SMN1; SMN2 (0.55) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943532 0.88 MAPT (0.43) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943588 0.85 ALDH1A1 (0.49) MAPTSMN1; SMN2KDM4ELMNANPC1
SCHEMBL11943590 0.83 ALDH1A1 (0.47) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943609 0.83 MAPT (0.50) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943192 0.83 MAPT (0.54) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943581 0.83 ALDH1A1 (0.46) MAPTRAB9ASMN1; SMN2LMNAPOLB
SCHEMBL11943583 0.82 ALDH1A1 (0.47) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943584 0.82 ALDH1A1 (0.46) MAPTRAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL11943540 0.81 ALDH1A1 (0.45) MAPTRAB9ASMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
WO-2008115381-A1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885RAB9A 4688/4885SMN1; SMN2 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.